Atossa Genetics Stock Net Income
| ATOS Stock | USD 1.28 0.01 0.78% |
Atossa Genetics fundamentals help investors to digest information that contributes to Atossa Genetics' financial success or failures. It also enables traders to predict the movement of Atossa Stock. The fundamental analysis module provides a way to measure Atossa Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atossa Genetics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -30.1 M | -28.6 M | |
| Net Loss | -29.8 M | -28.3 M | |
| Net Loss | -24.3 M | -25.5 M | |
| Net Loss | (0.24) | (0.25) | |
| Net Income Per E B T | 1.12 | 1.21 |
Atossa | Net Income |
Atossa Genetics Company Net Income Analysis
Atossa Genetics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Atossa Genetics Net Income | (30.09 M) |
Most of Atossa Genetics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atossa Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atossa Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Atossa Genetics is extremely important. It helps to project a fair market value of Atossa Stock properly, considering its historical fundamentals such as Net Income. Since Atossa Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atossa Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atossa Genetics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Atossa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Atossa Genetics reported net income of (30.09 Million). This is 108.82% lower than that of the Health Care Equipment & Supplies sector and 142.96% lower than that of the Health Care industry. The net income for all United States stocks is 105.27% higher than that of the company.
Atossa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Genetics could also be used in its relative valuation, which is a method of valuing Atossa Genetics by comparing valuation metrics of similar companies.Atossa Genetics is currently under evaluation in net income category among its peers.
Atossa Genetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Atossa Genetics from analyzing Atossa Genetics' financial statements. These drivers represent accounts that assess Atossa Genetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atossa Genetics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.0M | 4.2M | 13.3M | 10.7M | 12.4M | 16.6M | |
| Enterprise Value | (4.2M) | (6.1M) | 809.6K | (28.8M) | (33.1M) | (31.5M) |
Atossa Genetics Institutional Holders
Institutional Holdings refers to the ownership stake in Atossa Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Atossa Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atossa Genetics' value.| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 170.7 K | Citadel Advisors Llc | 2024-09-30 | 161.9 K | Qube Research & Technologies | 2024-06-30 | 157.4 K | Rhumbline Advisers | 2024-06-30 | 135.1 K | Mariner Wealth Advisors Llc | 2024-06-30 | 105.9 K | Bank Of America Corp | 2024-06-30 | 105.7 K | Goldman Sachs Group Inc | 2024-06-30 | 102.7 K | Two Sigma Investments Llc | 2024-09-30 | 96.2 K | Citigroup Inc | 2024-09-30 | 92 K | Blackrock Inc | 2024-06-30 | 9.2 M | Vanguard Group Inc | 2024-09-30 | 6.6 M |
Atossa Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 87.52 M | ||||
| Shares Outstanding | 125.8 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Shares Owned By Institutions | 28.20 % | ||||
| Number Of Shares Shorted | 12.45 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 2.20 X | ||||
| EBITDA | (31.35 M) | ||||
| Net Income | (30.09 M) | ||||
| Cash And Equivalents | 125.54 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 5.24 M | ||||
| Current Ratio | 35.19 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (20.94 M) | ||||
| Short Ratio | 20.27 X | ||||
| Earnings Per Share | (0.21) X | ||||
| Target Price | 5.83 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 161.03 M | ||||
| Total Asset | 96.25 M | ||||
| Retained Earnings | (186.29 M) | ||||
| Working Capital | 112.63 M | ||||
| Current Asset | 4.29 M | ||||
| Current Liabilities | 2.5 M | ||||
| Net Asset | 96.25 M |
About Atossa Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atossa Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.